Certified by Founder Lodge
Epsilogen Ltd
United Kingdom - Hammersmith
START UP
1 Disclosed Funding Rounds $16,370,899
0 Participating Investments
-
Founded date
2016
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours includi
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| September, 10 ,2024 | Series B | $16,370,899 |
British Patient Capital
3B Future Health Fund I & II
Epidarex Capital
ALSA Ventures
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Forage | $40,000,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
